SurvivorNet on MSN
A new all oral treatment for AML on the horizon for patients struggling to withstand chemo
Inqovi for AML treatment ...
Fatigue is a key prognostic indicator for adverse outcomes in AML, ALL, and myelodysplastic syndromes. CAR T-cell therapy post-transplant shows a 48% complete remission rate in AML, though not ...
Amgen acquires Dark Blue Therapeutics to fight Acute Myeloid Leukemia. See how this $840M deal aims to deliver first-in-class ...
Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
Recent market comparisons indicate that SMEs are prioritizing AML solutions that combine comprehensive screening capabilities with predictable pricing and manageable system requirements. This shift ...
Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results